Use of first-line (1L) OPDIVO® (nivolumab) in combination with low-dose YERVOY® (ipilimumab) in certain patients with metastatic NSCLC with PD‑L1 expression ≥1%

The Lynx Group: 2021 Ask The Expert MDietrich.pdf
Please Click the Issue to Download


This resource provides insights and guidance by a thought leader into frequently asked questions on the open-label, phase 3, Checkmate 227 study evaluating the use of 1L nivolumab in combination with low-dose ipilimumab in patients with metastatic NSCLC and PD-L1 ≥1%. It was recently updated to include 4-year extended follow-up data for the Checkmate 227 study, with a median follow-up of 54.8 months, presented by researchers at the American Society of Clinical Oncology 2021 annual meeting.

Download to Continue Reading

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: